Erasca Announces Strategic In-Licensing of RAS-Targeting : v

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors ...

Related Keywords

China , Macau , Hong Kong , United States , Joyce Allaire , Exchange Commission , Joyo Pharmatech Co Ltd , Nasdaq , Medshine Discovery Inc , Lifesci Advisors , Erasca Inc , Licensed Programs , New Drug Application , Medshine Discovery , Pipeline Prioritization , Private Securities Litigation Reform Act , Sci Advisors ,